New Hope for Breast Cancer Patients as NHS Approves Life-Extending Drug

Thousands of women in England living with a specific form of incurable breast cancer have received life-changing news. Starting this week, the National Health Service (NHS) will provide a drug called Enhertu to patients with HER2-low advanced breast cancer. This decision marks the end of a long and difficult two-year wait for many families, as the treatment was previously rejected by the National Institute for Health and Care Excellence (NICE) because it was considered too expensive.

NICE is the organization that advises the NHS on whether medical treatments offer good value for money. In July 2024, they decided that the cost of Enhertu was too high to justify its use. However, after persistent campaigning from charities, doctors, and patients, the government and the drug’s makers—AstraZeneca and Daiichi Sankyo—returned to the negotiating table. According to The Guardian, the breakthrough came after a change in policy allowed the NHS to spend more on individual patient treatments, raising the limit from £30,000 to £35,000 per year.

For many, this news brings a mix of relief and deep sadness. Kate Wills, a 51-year-old mother living with stage four cancer, told the BBC that the news gave her "enormous hope." She explained that she now dares to dream of seeing her children grow up, get married, and fall in love. Yet, she also noted that the moment is bittersweet, as she thinks of friends who did not survive long enough to receive the treatment. Claire Rowney, chief executive of the charity Breast Cancer Now, echoed these feelings. While she called the decision a "milestone victory," she also stated that the country cannot celebrate without remembering the "devastating cost" of the two-year delay.

Enhertu is a targeted treatment that works differently than standard chemotherapy. Dr. Catherine Elliott, a director at Cancer Research UK, explained that the drug delivers medicine directly to cancer cells. Clinical trials have shown that this approach is highly effective. For patients with HER2-low advanced breast cancer, the drug can help them live longer and slow the progress of the disease. On average, patients using Enhertu gained about 6.6 months of extra life compared to those using standard treatments, with some individuals living up to three years longer.

This change brings England in line with other parts of the United Kingdom and Europe. Patients in Scotland have had access to the drug since 2023, and it is currently available in 26 other European countries. Following the announcement, officials indicated that doctors in Northern Ireland can now prescribe the drug, and Wales is expected to follow the same path shortly. Health Secretary Yvette Cooper praised the efforts of the campaigners, stating that the recommendation is a "tribute" to the charities that never stopped fighting for access.

Despite the success of the new deal, questions remain about how the agreement was reached. The BBC reported that the drug companies did not significantly lower their prices during the negotiations. Instead, the reversal by NICE was largely made possible by a new financial arrangement involving the UK government and the United States. This "commercial solution" allowed the NHS to finally add the drug to its list of approved treatments.

For the approximately 1,000 women in England who will benefit from this decision each year, the impact is profound. While the journey to this point was long and often painful, the availability of Enhertu provides a new, essential option for those facing the most difficult health challenges. As Dr. Anne Rigg, an NHS national advisor, noted, this is "hugely positive news" for women who will now have the opportunity to gain precious time with their loved ones.